Anti-LAG-3 binding proteins

Abstract

Antigen binding proteins that bind Lymphocyte Activation Gene 3 (LAG-3), and more particularly to antigen binding proteins that cause depletion of LAG-3+ activated T cells.

The invention claimed is: 
     
       1. An antigen binding protein which is capable of binding Lymphocyte Activation Gene 3 (LAG-3) and which comprises CDRL1, CDRL2 and CDRL3 from SEQ ID NO:5 and CDRH1, CDRH2 and CDRH3 from SEQ ID NO:10. 
     
     
       2. The antigen binding protein according to  claim 1 , wherein the antigen binding protein is capable of binding LAG-3 expressed on activated T-cells. 
     
     
       3. The antigen binding protein according to  claim 1 , wherein the antigen binding protein comprises a human IgG1 constant region and is capable of depleting LAG-3+ activated human T-cells. 
     
     
       4. The antigen binding protein according to  claim 1 , wherein the antigen binding protein is a humanised antibody. 
     
     
       5. The humanised antibody according to  claim 4 , wherein the humanised antibody comprises a human IgG1 constant region. 
     
     
       6. The humanised antibody according to  claim 5 , which is non-fucosylated. 
     
     
       7. A humanised antibody comprising the variable light chain (VL) of SEQ ID NO:4 and the variable heavy chain (VH) of SEQ ID NO:9, wherein the antibody does not comprise fucose on the core carbohydrate structure attached to Asn297. 
     
     
       8. An antigen binding protein as produced by a host cell that comprises an expression vector that comprises a nucleic acid molecule which encodes an antigen binding protein of  claim 1 . 
     
     
       9. A method of producing an antigen binding protein, comprising a) culturing a host cell that comprises an expression vector that comprises a nucleic acid molecule which encodes an antigen binding protein of  claim 1  under conditions suitable to express the antigen binding protein and b) isolating the antigen binding protein. 
     
     
       10. A pharmaceutical composition comprising a) an antigen binding protein according to  claim 1 , and b) a pharmaceutically acceptable carrier. 
     
     
       11. The antigen binding protein of  claim 8 , wherein the FUT8 gene encoding alpha-1,6-fucosyltransferase has been inactivated in the host cell.